menu
    • menu
    [{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"Boundless Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I","graph3":"Leaps by Bayer","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"Senti Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Leaps by Bayer","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Oral Inhalation","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"Senti Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Leaps by Bayer","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"GRO Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Leaps by Bayer","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"NextPoint","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leaps by Bayer","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"Indapta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leaps by Bayer","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"Azitra","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Acetoacetyl-CoA thiolase (ACAT1)","graph1":"Dermatology","graph2":"Preclinical","graph3":"Leaps by Bayer","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"Bloom Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Series A Financing","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Leaps by Bayer","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"},{"orgOrder":0,"company":"Leaps by Bayer","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Leaps by Bayer","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0.20000000000000001,"dosageForm":"Aerosol","sponsorNew":"Leaps by Bayer \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Leaps by Bayer \/ Leaps by Bayer"}]

    Find Clinical Drug Pipeline Developments & Deals by Leaps by Bayer

    Menu

    Leaps by Bayer

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : NextPoint

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures t...

                            Details : The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : NextPoint

                            Deal Size : $80.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Indapta Therapeutics

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell T...

                            Details : The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : IDP-023,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Indapta Therapeutics

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBI-355

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Boundless Bio

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Boundless Bio Announces $100 Million Series C Financing co-led by Leaps by Bayer and RA Capital Management to ...

                            Details : Boundless Bio will use the financing to advance BBI-355, a potentially best-in-class checkpoint kinase 1 inhibitor and the first ecDNA-directed therapy, through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncog...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 16, 2023

                            Lead Product(s) : BBI-355

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Boundless Bio

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Recipient : ReCode Therapeutics

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with ...

                            Details : Proceeds from the financing will be used to fund the diversification of ReCode’s pipeline into central nervous system, liver, and oncology indications, while continuing to advance lead mRNA programs for primary ciliary dyskinesia and cystic fibrosis in...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 29, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Recipient : ReCode Therapeutics

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Senti Biosciences

                            Deal Size : $5.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combinatio...

                            Details : Senti’s existing investors continue to support the mission of engineering gene circuits with programmable logic in cell and gene therapies, and progress in advancing multiple oncology programs including SENTI-202, towards the clinic.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 24, 2022

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Senti Biosciences

                            Deal Size : $5.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BL-001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Bloom Science

                            Deal Size : $12.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Bloom Science Raises USD $12 Million in Series A Financing

                            Details : The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent a...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            September 12, 2021

                            Lead Product(s) : BL-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Bloom Science

                            Deal Size : $12.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Senti Biosciences

                            Deal Size : $105.0 million

                            Deal Type : Series B financing

                            DEALS_DEV arrow-down

                            Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene ...

                            Details : Proceeds from the Series B financing will support scale up of clinical manufacturing, including process development and design of a cGMP-compliant manufacturing facility for off-the-shelf allogeneic CAR-NK cell product candidates.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 01, 2021

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Senti Biosciences

                            Deal Size : $105.0 million

                            Deal Type : Series B financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : GRO Biosciences

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group

                            Details : The proceeds will support development of the GRO platform, scale-up of bioprocess manufacturing, preclinical validation studies and IND-enabling studies for GRObio’s pipeline of unique non-standard amino acid protein therapeutics to treat autoimmune an...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : GRO Biosciences

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed

                            Leaps by Bayer

                            Germany arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-01

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Recipient : Azitra

                            Deal Size : $17.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra

                            Details : The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products and co...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 15, 2020

                            Lead Product(s) : ATR-01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Recipient : Azitra

                            Deal Size : $17.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth